Generated by All in One SEO v4.9.10, this is an llms.txt file, used by LLMs to index the site.
# BioAtla
Rebolutionizing Cancer Therapy
## Sitemaps
- [XML Sitemap](https://www.bioatla.com/sitemap.xml): Contains all public & indexable URLs for this website.
## Posts
- [BIOATLA REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS](https://www.bioatla.com/news/bioatla-reports-second-quarter-2022-financial-results-and-highlights-recent-progress/) - BIOATLA REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS– Mecbotamab vedotin (BA3011) Phase 2 preliminary observations in Non-Small Cell Lung Carcinoma (NSCLC) supports advancing to the registrational stage of the study; anticipate full interim data set in 4Q22– Mecbotamab vedotin (BA3011) Undifferentiated Pleomorphic Sarcoma (UPS) and osteosarcoma Phase 2 part 2 enrollment anticipated
- [BioAtla to Participate in 2022 Jefferies Global Healthcare Conference](https://www.bioatla.com/news/bioatla-to-participate-in-2022-jefferies-global-healthcare-conference/) - SAN DIEGO, June 01, 2022 -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder, and Scott Smith, President, will provide a corporate update and
- [FIRST PATIENTS DOSED IN PHASE 2 PLATFORM CLINICAL TRIAL TESTING NOVEL IMMUNOTHERAPY COMBINATIONS IN HIGHLY MALIGNANT OVARIAN CANCER](https://www.bioatla.com/news/first-patients-dosed-in-phase-2-platform-clinical-trial-testing-novel-immunotherapy-combinations-in-highly-malignant-ovarian-cancer/) - Patients with ovarian cancer of the high-grade serous carcinoma subtype and that no longer respond to treatment with platinum-based therapy will receive a PD-L1-blocking antibody along with one of two antibody-drug conjugates targeting overexpressed receptor tyrosine kinases in the first two cohorts of this studyMultiple sites across Canada and the U.S. open in 2022Combination immunotherapy
- [BIOATLA REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS](https://www.bioatla.com/news/bioatla-reports-first-quarter-2022-financial-results-and-highlights-recent-progress/) - Mecbotamab vedotin (BA3011) sarcoma Phase 2 top-line interim data support advancing with UPS and osteosarcoma – Mecbotamab vedotin (BA3011) Phase 2 interim analysis in NSCLC anticipated in first half 2022; interim update projected on 2Q22 earnings call – Ozuriftamab vedotin (BA3021) NSCLC Phase 2 preliminary cohort enrollment completion and interim update anticipated in second half of 2022
- [BioAtla to Announce First Quarter 2022 Financial Results and Provide Business Highlights on May 4, 2022](https://www.bioatla.com/news/bioatla-to-announce-first-quarter-2022-financial-results-and-provide-business-highlights-on-may-4-2022/) - SAN DIEGO, April 8, 2022 -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody and other protein therapeutics, today announced that it plans to host a conference call and webcast on Wednesday, May 4, 2022 at 4:30 p.m. Eastern Time to discuss its financial
- [BIOATLA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS](https://www.bioatla.com/news/bioatla-announces-fourth-quarter-and-full-year-2021-financial-results/) - Mecbotamab vedotin (BA3011) sarcoma Phase 2 top-line interim update expected in first quarter results conference call. NSCLC Phase 2 interim update expected in first half 2022.Ozuriftamab vedotin (BA3021) continues with enrollment of patients in Phase 2 clinical studies in NSCLC and melanoma. Expect mid-year initial interim update for NSCLC and melanoma. Phase 2 study in
- [BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (nivolumab) for Treatment of Solid Tumors](https://www.bioatla.com/news/bioatla-announces-clinical-collaboration-bristol-myers-squibb-study-mecbotamab-vedotin-ba3011-ozuriftamab-vedotin-ba3021-combination-opdivo-nivolumab-treatment/) - SAN DIEGO, CA – January 10, 2022 - BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to investigate BioAtla’s two lead CAB-ADC candidates, BA3011 and BA3021, in
- [BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS](https://www.bioatla.com/news/bioatla-appoints-edward-l-williams-board-directors/) - SAN DIEGO, CA – December 21, 2021 - BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Edward L. (Eddie) Williams has been appointed to the BioAtla Board of Directors and has agreed to serve on the Audit Committee of the Board. Mr.
- [BIOATLA TO PRESENT AT 40TH ANNUAL J.P. MORGAN VIRTUAL HEALTHCARE CONFERENCE](https://www.bioatla.com/news/bioatla-present-40th-annual-j-p-morgan-virtual-healthcare-conference/) - Phase 2 Clinical Trial Update Will Be Provided SAN DIEGO, CA – December 20, 2021 - BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Jay M. Short, Ph.D., Chief Executive Officer, and Scott Smith, President, with participation by other BioAtla executives, will present
- [BIOATLA ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CLINICAL AND BUSINESS UPDATE](https://www.bioatla.com/news/bioatla-announces-third-quarter-2021-financial-results-provides-clinical-business-update/) - Mecbotamab vedotin (BA3011 ) sarcoma Phase 2 interim data read-out on-schedule for year end. Phase 1 sarcoma data presented at recent CTOS 2021 annual meetingMecbotamab vedotin (BA3011) and ozuriftamab vedotin (BA3021) continue to advance through Phase 2 in multiple indications CAB-CTLA-4 Phase 1/2 clinical trial planned to be initiated by year endAdvancing several CAB bispecific
- [BIOATLA ANNOUNCES PRIVATE PLACEMENT OF 2.7 MILLION SHARES](https://www.bioatla.com/news/bioatla-announces-private-placement-2-7-million-shares/) - Proceeds to advance CAB-AXL and CAB-ROR2 through potentially registration enabling Phase 2 clinical trials, and additional CAB development programs SAN DIEGO, CA – September 29, 2021 - BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into stock purchase
- [BIOATLA ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE](https://www.bioatla.com/news/bioatla-announces-second-quarter-2021-financial-results-provides-clinical-update/) - $207.6 million cash balance expected to provide funding for operations into 2023Continue to advance potentially registration enabling Phase 2 studies for mecbotamab vedotin (BA3011) and ozuriftamab vedotin (BA3021) in several indications in the U.S. and in Asia with first patient dosed in TaiwanAdvancing several CAB bispecific and antibody drug conjugate (“ADC”) product candidates in preclinical
- [BIOATLA ANNOUNCES FIRST QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE](https://www.bioatla.com/news/bioatla-announces-first-quarter-2021-financial-results-provides-business-update/) - Initiated potentially registration-enabling Phase 2 studies for our CAB-AXL-ADC in refractory sarcoma patients and NSCLC patients refractory to EGFR or PD-1/L1 inhibitorsInitiated potentially registration-enabling Phase 2 studies for our CAB-ROR2-ADC in NSCLC and melanoma patients refractory to PD-1/L1 inhibitorsAdvanced several CAB bispecific product candidates in preclinical development$221 million cash balance expected to provide funding for
- [BIOATLA ANNOUNCES FULL YEAR 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE](https://www.bioatla.com/news/bioatla-announces-full-year-2020-financial-results-provides-business-update/) - Year end $239 million cash balance, primarily generated from net proceeds from December IPO and July private placement, and is expected to provide funding at least through end of 2022Conducting Phase 2 clinical trials for CAB-AXL-ADC and CAB-ROR2-ADC and with BeiGene initiating CAB-CTLA4 Phase 1 trialPotentially registration-enabling Phase 2 clinical trials for CAB-AXL-ADC, in treatment
- [BIOATLA CONDITIONALLY ACTIVE BIOLOGIC ANTIBODY DESIGN AND FUNCTIONALITY FOR CANCER TREATMENT DESCRIBED IN LEADING SCIENTIFIC JOURNAL PEER-REVIEWED PAPER](https://www.bioatla.com/news/bioatla-conditionally-active-biologic-antibody-design-functionality-cancer-treatment-described-leading-scientific-journal-peer-reviewed-paper/) - BioAtla Scientists Discover Novel pH Mechanism Published in Proceedings of the National Academy of Sciences SAN DIEGO, CA - February 22, 2021 - BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced the publication by Proceedings of the National Academy of Sciences (PNAS) that describes
- [BIOATLA TO PRESENT AT 39TH ANNUAL J.P. MORGAN VIRTUAL HEALTHCARE CONFERENCE](https://www.bioatla.com/news/bioatla-present-39th-annual-j-p-morgan-virtual-healthcare-conference/) - SAN DIEGO, CA - January 8, 2021 - BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Jay M. Short, Ph.D., Chief Executive Officer, and Scott Smith, President, with participation by other BioAtla executives, will present at the 39th Annual J.P. Morgan Virtual
- [BioAtla Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares](https://www.bioatla.com/news/bioatla-announces-closing-initial-public-offering-full-exercise-underwriters-option-purchase-additional-shares/) - December 18, 2020SAN DIEGO, Calif., December 18, 2020 -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer, today announced the closing of its initial public offering of 12,075,000 shares of common stock at a public offering price
- [BIOATLA ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING](https://www.bioatla.com/news/bioatla-announces-pricing-initial-public-offering/) - December 15, 2020SAN DIEGO, Calif., December 15, 2020 -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer, today announced the pricing of its initial public offering of 10,500,000 shares of common stock at a public offering price
- [BIOATLA AND BEIGENE REVISE GLOBAL DEVELOPMENT AND COMMERCIALIZATION AGREEMENT](https://www.bioatla.com/news/bioatla-beigene-revise-global-development-commercialization-agreement/) - San Diego, CA; Beijing, China and Cambridge, MA - October 6, 2020 - BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) protein therapeutics, and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), a commercial-stage biotechnology company, today announced that the two companies have revised their previous global co-development and
- [BIOATLA RAISES $72.5 MILLION IN SERIES D FINANCING](https://www.bioatla.com/news/bioatla-raises-72-5-million-series-d-financing/) - Proceeds will advance CAB-AXL and CAB-ROR2 clinical programs into Phase 2 trials, CAB-CTLA-4 Phase 1 trial, and additional CAB development programs SAN DIEGO, CA - July 15, 2020 - BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced closing of a Series D financing
- [BIOATLA APPOINTS ERIC SIEVERS, M.D., AS CHIEF MEDICAL OFFICER](https://www.bioatla.com/news/bioatla-appoints-eric-sievers-m-d-chief-medical-officer/) - Experienced leader of oncology clinical trial approvals to head BioAtla's clinical development programs SAN DIEGO, CA - June 28, 2019 - BioAtla, LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced the appointment of Eric L. Sievers, M.D., as chief medical officer. Dr. Sievers, an experienced
- [BIOATLA SUBSIDIARY, HIMALAYA THERAPEUTICS, WILL DEVELOP AND COMMERCIALIZE CAB PRODUCTS IN GREATER CHINA MARKET](https://www.bioatla.com/news/bioatla-subsidiary-himalaya-therapeutics-will-develop-commercialize-cab-products-greater-china-market/) - First Conditionally Active Biologics licensing participation in Greater China territorySan Diego, CA - April 16, 2019 - BioAtla©, LLC, a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) protein therapeutics for the oncology market, today announced that Himalaya Therapeutics SEZC, a Cayman Island corporation and majority owned subsidiary of BioAtla,
- [BIOATLA AND BEIGENE FORM WORLDWIDE COLLABORATION TO DEVELOP AND COMMERCIALIZE NOVEL CONDITIONALLY ACTIVE BIOLOGIC CTLA-4 THERAPY](https://www.bioatla.com/news/bioatla-and-beigene-form-worldwide-collaboration/) - Plan to pursue development as a monotherapy and in combination with BeiGene's investigational anti-PD-1 antibody, tislelizumab San Diego, CA; Beijing, China and Cambridge, MA, - April 8, 2019 - BioAtla ©, LLC, a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) protein therapeutics, and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), a
- [BIOATLA PRESENTS CAB-CTLA-4 AND CAB-EpCAM-ADC DATA AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING](https://www.bioatla.com/news/bioatla-presents-cab-ctla-4-cab-epcam-adc-data-american-association-cancer-research-annual-meeting/) - Oral presentation highlights CAB-CTLA-4 pre-clinical data demonstrating expected efficacy and reduced immune side effects and toxicities as monotherapy or in combination with PD-1 inhibitors Poster presentation of CAB-EpCAM-ADC demonstrating anti-tumor efficacy in vivo San Diego, CA - February 27, 2019 - BioAtla ©, LLC, a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic
- [BIOATLA CONGRATULATES JAMES ALLISON, PH.D. FOR RECEIVING NOBEL PRIZE](https://www.bioatla.com/news/bioatla-congratulates-james-allison-ph-d-receiving-nobel-prize/) - Drs. Allison and Sharma advising BioAtla on its CAB-CTLA4 antibody drug candidate and other proprietary CAB programs and the design of combination therapies SAN DIEGO, CA - October 4, 2018 - BioAtla, LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, congratulates James Allison, Ph.D., for receiving the 2018
- [BIOATLA APPOINTS SCOTT SMITH AS PRESIDENT](https://www.bioatla.com/news/bioatla-appoints-scott-smith-president/) - Experienced biopharmaceutical executive to drive expansion of operations, product strategy and corporate partnering efforts SAN DIEGO, CA - September 10, 2018 - BioAtla, LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced the appointment of Scott Smith, as President. Mr. Smith, an experienced biotechnology and pharmaceutical
- [BIOATLA APPOINTS LAWRENCE FONG, M.D. AS SCIENTIFIC ADVISOR](https://www.bioatla.com/news/bioatla-appoints-lawrence-fong-m-d-scientific-advisor/) - Leading clinical researcher in cancer immunotherapy will advise BioAtla on clinical trial designs of the company's proprietary CABs in combination therapies SAN DIEGO, CA - July 24, 2018 - BioAtla, LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced the appointment of Lawrence Fong, M.D., as
- [BIOATLA ANNOUNCES FIRST PATIENT TREATED IN PHASE1/2 BA3021-001 CLINICAL TRIAL FOR CAB-ROR2-ADC THERAPEUTIC](https://www.bioatla.com/news/bioatla-announces-first-patient-treated-phase1-2-ba3021-001-clinical-trial-cab-ror2-adc-therapeutic/) - CAB-ROR2-ADC in clinical testing for treatment of several solid tumor types SAN DIEGO, CA - June 28, 2018 - BioAtla, LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) protein therapeutics, announced today the treatment of the first patient in its clinical trial BA3021-001 for BioAtla's BA3021, a novel conditionally
- [BioAtla Announces FDA Clearance of Investigational New Drug Application For CAB-ROR2-ADC Therapeutic](https://www.bioatla.com/news/bioatla-announces-fda-clearance-investigational-new-drug-application-cab-ror2-adc-therapeutic/) - CAB-ROR2-ADC to be clinically tested for treatment of several solid tumor cancers SAN DIEGO, CA - April 16, 2018 - BioAtla, LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) protein therapeutics, announced today the U.S. Food and Drug Administration (FDA) has cleared BioAtla's Investigational New Drug application (IND) for
- [BioAtla Announces First Patient Treated in CAB-AXL-ADC Phase 1/2 Clinical Trial BA3011-001](https://www.bioatla.com/news/first-patient-treated-in-cab-axl-adc-phase-1-2-clinical-trial/) - CAB-AXL-ADC in clinical testing for treatment of several solid tumor cancers SAN DIEGO, CA - February 28, 2018 - BioAtla© LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) protein therapeutics, announced today the treatment of the first patient in its clinical trial BA3011-001 for BioAtla's BA3011, a novel conditionally
- [BioAtla Announces FDA Clearance of IND Application for CAB-AXL-ADC Therapeutic](https://www.bioatla.com/news/bioatla-ind-for-cab-axl-adc-cleared-by-fda/) - CAB-AXL-ADC to be clinically tested for treatment of several solid tumor cancers SAN DIEGO, CA - January 24, 2018 - BioAtla© LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) protein therapeutics, announced today the U.S. Food and Drug Administration (FDA) has cleared BioAtla's Investigational New Drug application (IND) for
- [Clinical Trial Utilizing BioAtla's Conditionally Active Biologics in CAR-T Candidates for Solid Tumors to be Initiated in China](https://www.bioatla.com/news/conditionally-active-car-t-enters-the-clinic-in-china/) - Axl and Ror2 targeted CAB-CAR-T cellular products to be tested in patients with refractory, metastatic kidney cancerSAN DIEGO, CA - January 8, 2018 - BioAtla© LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) protein therapeutics, announced today that Shanghai Sinobioway Sunterra Biotechnology, a partner of F1 Oncology, Inc., has
- [BioAtla® Appoints James Allison PhD and Padmanee Sharma MD PhD as Scientific Advisors](https://www.bioatla.com/news/dr-jim-allison-and-dr-padmanee-sharma-join-bioatla-as-scientific-advisors/) - Leading researchers in immuno-oncology will advise BioAtla on company's proprietary CAB programs and design of combination therapiesSAN DIEGO, CA - November 16, 2017 - BioAtla, LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced the appointments of James Allison, Ph.D. and Padmanee Sharma, M.D., Ph.D. as scientific
- [BioAtla® Receives Broad Patent Covering Conditionally Active Biologics](https://www.bioatla.com/news/bioatla-issued-patent-for-conditionally-active-biologics/) - Proprietary "Smart Antibodies" Allow for Selective Activation in Cancerous Tissues San Diego, Calif. - April 30, 2014 - BioAtla©, a global biotechnology company focused on the development of differentiated biological therapeutics, today announced that the United States Patent and Trademark Office (USPTO) has issued to BioAtla©U.S. Patent No. 8,709,755, its first patent directed to methods
- [BioAtla® Receives $30M Equity Investment from China-based Investor Group](https://www.bioatla.com/news/bioatla-30m-equity-investment-from-china/) - Proceeds to accelerate proprietary product development and create opportunities in the Chinese pharmaceutical market San Diego, Calif. - June 11, 2015 - BioAtla©LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that a China-based investor group has purchased $30 million in BioAtla©equity. The proceeds will be
- [BioAtla® and Sinobioway Select First Program for Strategic Collaboration in China Market](https://www.bioatla.com/news/sinobioway-selects-first-bioatla-program-for-china/) - BioAtla© receives $19 million in first program payments plus equity SAN DIEGO, CA - January 6, 2016 - BioAtla© LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that BioAtla© and Beijing Sinobioway Group Company, Limited (Sinobioway) selected their first product programs for development. In May
- [BioAtla® and Sinobioway Complete Selection of First Four Programs for Strategic Collaboration in China Market](https://www.bioatla.com/news/sinobioway-selects-four-bioatla-programs-for-china/) - BioAtla© receives $36 million as balance of 2016 CAB program selection paymentsSAN DIEGO, CA - December 6, 2016 - BioAtla© LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that BioAtla© and Beijing Sinobioway Group Company, Limited (Sinobioway) selected their first four CAB product programs for development. The
- [BioAtla® and Sinobioway Expand Collaboration Agreement and Enter Into Services Agreement](https://www.bioatla.com/news/bioatla-sinobioway-expand-partnership/) - Five new CAB antibody candidates to be selected New services agreement provides for discounted development and manufacturing costsSAN DIEGO, CA - May 16, 2017 - BioAtla© LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that BioAtla and Beijing Sinobioway Group Company, Limited (Sinobioway) expanded their CAB development
- [BioAtla® and F1 Oncology Announce Collaboration to Develop CAB-CAR-T's for Solid Tumors](https://www.bioatla.com/news/f1-cab-car-t-for-solid-tumors/) - Sinobioway affiliates and US entities invest $37M in F1 Oncology, Inc. First clinical trial with CAB CAR-T in solid tumors planned for China in 2017SAN DIEGO, CA and WEST PALM BEACH, FL - January 6, 2017 - BioAtla© LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) protein therapeutics, and F1 Oncology, Inc.,
- [Bioatla® Profiled in Nature Biopharma Dealmakers](https://www.bioatla.com/news/profile-in-nature-biopharma-dealmakers/) - The September 2014 issue of Nature Biopharma Dealmakers focused on innovative biotech companies in the field of cancer immunotherapy, and featured a profile of Bioatla© and their Conditionally Active Biologics (CAB) technology. With this technology antibodies can be engineered for activity only in certain microenvironments (for example the acidic microenvironment of tumor cells), thereby enhancing safety and therapeutic
- [Bioatla® Receives Broad Patent for Antibody Development](https://www.bioatla.com/news/bioatla-receives-broad-patent-for-antibody-development/) - CIAO!™ Technology Maximizes Selectivity of Conditionally Active Antibodies San Diego, Calif. - October 14, 2014 - BioAtla©, a global biotechnology company focused on the development of Conditionally Active Biologics (CABs), today announced that the United States Patent and Trademark Office (USPTO) has issued to BioAtla U.S. Patent No. 8,859,467, for its proprietary Comprehensive Integrated Antibody
## Pages
- [Home](https://www.bioatla.com/)
- [Strategic Relationships](https://www.bioatla.com/strategic-relationships/)
- [About Us](https://www.bioatla.com/about/) - About Us Profile BioAtla© develops novel therapies with improved therapeutic index that have the potential to revolutionize cancer treatment. BioAtla© is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics™ (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!™) platforms. These and other proprietary technologies (protected by
- [Conditionally Active Biologics™ (CAB)](https://www.bioatla.com/technology/cab/) - 4th Generation Antibody Therapeutics CAB BioAtla© is developing CAB versions of immune checkpoint antibodies to enable combination therapy without the toxicity. Empty Link CAB-ADC CAB technology enables more safe and potent ADC's, as well as cancer targets also found in normal tissue. Empty Link CAB-CAR-T CAB technology can improve the safety and potency of CAR-T
- [Expanded Access Policy](https://www.bioatla.com/expanded-access-policy/) - Expanded Access Policy About BioAtla BioAtla Inc. (“BioAtla” or “us,”we,” “our”) is a clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors. Clinical trials form the foundation of our development programs. These trials are designed to assess the safety, tolerability and efficacy of investigational
- [CAB Portfolio](https://www.bioatla.com/cab-portfolio/) - CAB Portfolio Robust Pipeline of Conditionally Active Biologic (CAB) Based Therapeutics Program Target IND Enabling Pre-Clinical Phase 1 Clinical Phase 2 Lead Indications BA3011 Mecbotamab Vedotin AXL STS & Bone Sarcoma NSCLC Ovarian Cancer* (Mono & Combo w/ PD-1) BA3021 Ozuriftamab Vedotin ROR2 NSCLC Melanoma HNC Ovarian Cancer* (Mono & Combo w/ PD-1) BA3071 Naked
- [Publications](https://www.bioatla.com/publications/)
- [Scientific Glossary](https://www.bioatla.com/appendix/scientific-glossary/) - Scientific Glossary
- [Contact](https://www.bioatla.com/contact/)
- [Appendix](https://www.bioatla.com/appendix/)
- [Cookie Policy](https://www.bioatla.com/cookie-policy/) - About this cookie policyThis Cookie Policy explains what cookies are and how we use them, the types of cookies we use i.e, the information we collect using cookies and how that information is used, and how to control the cookie preferences. For further information on how we use, store, and keep your personal data secure,
- [test](https://www.bioatla.com/test/) - https://www.bioatla.com/wp-content/uploads/2023/01/BioAtla-Privacy-Policy.pdf
- [Personal Data Request](https://www.bioatla.com/personal-data-request/)
- [News](https://www.bioatla.com/news/)
- [General Purchase Order Terms and Conditions](https://www.bioatla.com/poterms/) - General Purchase Order Terms and Conditions Applicability This purchase order is an offer by BioAtla, Inc. (the "Buyer") to purchase the goods ("Goods") and/or services ("Services") from the seller ("Seller") named in this purchase order (the "Order"), which purchase is governed solely by these terms and conditions (“Terms”). Notwithstanding anything herein to the contrary, if
- [Privacy Policy](https://www.bioatla.com/privacy-policy/) - Privacy Policy Thank you for visiting bioatla.com. This privacy policy tells you how we use personal information collected at this site. Please read this privacy policy before using the site or submitting any personal information. By using the site, you are accepting the practices described in this privacy policy. You are encouraged to review the
- [Comprehensive Integrated Antibody Optimization (CIAO!™)](https://www.bioatla.com/technology/ciao/) - Comprehensive Integrated Antibody Optimization
- [Tumor Microenvironment](https://www.bioatla.com/appendix/tumor-microenvironment/)
- [Antibody Drug Nomenclature](https://www.bioatla.com/appendix/antibody-nomenclature/)
- [Antibody Isotype](https://www.bioatla.com/appendix/antibody-isotype/)
- [Antibody Structure](https://www.bioatla.com/appendix/antibody-structure/)
- [Technology](https://www.bioatla.com/technology/)
- [Clinical Process](https://www.bioatla.com/appendix/clinical-process/)
- [Site Map](https://www.bioatla.com/site-map/)
## Publications
- [Median OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC](https://www.bioatla.com/news/publication/median-os-of-21-5-months-among-44-patients-with-treatment-refractory-leiomyosarcoma-liposarcoma-and-undifferentiated-pleomorphic-sarcoma-treated-with-mecbotamab-vedotin-an-axl-targeting-adc/)
- [Targeting HPV E6/E7 Upregulation of ROR2 with Oz-V in OPSCC](https://www.bioatla.com/news/publication/targeting-hpv-e6-e7-upregulation-of-ror2-with-oz-v-in-opscc/)
- [T-cell Engager in Patients with Treatment Refractory Metastatic Adenocarcinoma](https://www.bioatla.com/news/publication/t-cell-engager-in-patients-with-treatment-refractory-metastatic-adenocarcinoma/)
- [First-in-Human Phase 1 Study of a Dual-Conditionally Active Biologic (CAB) EpCAM x CD3 Bispecific T-cell Engager (TCE), BA3182, in Patients with Treatment Refractory Metastatic Adenocarcinoma](https://www.bioatla.com/news/publication/first-in-human-phase-1-study-of-a-dual-conditionally-active-biologic-cab-epcam-x-cd3-bispecific-t-cell-engager-tce-ba3182-in-patients-with-treatment-refractory-metastatic-adenocarcinoma/)
- [Preliminary Results from a First-in-Human Phase 1 Study of a Dual-Conditionally Binding CAB-EpCAM x CAB-CD3 Bispecific T-cell Engager, BA3182, in Patients with Treatment Refractory Metastatic Adenocarcinoma](https://www.bioatla.com/news/publication/preliminary-results-from-a-first-in-human-phase-1-study-of-a-dual-conditionally-binding-cab-epcam-x-cab-cd3-bispecific-t-cell-engager-ba3182-in-patients-with-treatment-refractory-metastatic-adenocar/)
- [Updated Results from a Study of Evalstotug (BA3071), an Anti–CTLA-4 Conditionally Active Biologic](https://www.bioatla.com/news/publication/updated-results-from-a-study-of-evalstotug-ba3071-an-anti-ctla-4-conditionally-active-biologic/)
- [Phase 2 Trial of Ozuriftamab Vedotin (Oz-V), a Conditionally Binding CAB-ROR2-ADC, in Patients with Heavily Pretreated Squamous Cell Carcinoma](https://www.bioatla.com/news/publication/phase-2-trial-of-ozuriftamab-vedotin-oz-v-a-conditionally-binding-cab-ror2-adc-in-patients-with-heavily-pretreated-squamous-cell-carcinoma/)
- [Identification of novel senolytic targets and development of Conditionally Active Biologic-based-drug conjugates for targeted senescence-associated secretory phenotype elimination in vivo](https://www.bioatla.com/news/publication/identification-of-novel-senolytic-targets-and-development-of-conditionally-active-biologic-based-drug-conjugates-for-targeted-senescence-associated-secretory-phenotype-elimination-in-vivo/)
- [BA3361, A Tumor Selective, Conditionally Active anti-Nectin4 ADC with a Novel NextGen Linker System has improved Efficacy in Pancreatic Cancer Models](https://www.bioatla.com/news/publication/ba3361-a-tumor-selective-conditionally-active-anti-nectin4-adc-with-a-novel-nextgen-linker-system-has-improved-efficacy-in-pancreatic-cancer-models/)
- [Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody–drug conjugate](https://www.bioatla.com/news/publication/preclinical-development-of-mecbotamab-vedotin-ba3011-a-novel-axl-specific-conditional-active-biologic-antibody-drug-conjugate/)
- [Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody–drug conjugate](https://www.bioatla.com/news/publication/preclinical-development-of-ozuriftamab-vedotin-ba3021-a-novel-ror2-specific-conditionally-active-biologic-antibody-drug-conjugate-2/)
- [Ozuriftamab Vedotin (BA3021), a Conditionally Binding ROR2-ADC in Patients with Heavily Pretreated Squamous Cell Carcinoma of the Head and Neck: Antitumor Activity Observed Among Patients with Both HPV Related and HPV-Negative Cancers](https://www.bioatla.com/news/publication/ozuriftamab-vedotin-ba3021-a-conditionally-binding-ror2-adc-in-patients-with-heavily-pretreated-squamous-cell-carcinoma-of-the-head-and-neck-antitumor-activity-observed-among-patients-with-both-h/)
- [Exploratory Analysis of Overall Survival among Non-Small Cell Lung Cancer (NSCLC) Patients with Mutated KRAS in a Phase 2 Trial of Mecbotamab Vedotin (CAB-AXL-ADC)](https://www.bioatla.com/news/publication/exploratory-analysis-of-overall-survival-among-non-small-cell-lung-cancer-nsclc-patients-with-mutated-kras-in-a-phase-2-trial-of-mecbotamab-vedotin-cab-axl-adc/)
- [Characterization of Mutated KRAS Genotype and Clinical Outcomes in Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, a CAB-AXL-ADC](https://www.bioatla.com/news/publication/characterization-of-mutated-kras-genotype-and-clinical-outcomes-in-patients-with-advanced-nsclc-treated-with-mecbotamab-vedotin-a-cab-axl-adc/)
- [BA3361, a NextGen CAB ADC Targeting Nectin4](https://www.bioatla.com/news/publication/ba3361-a-nextgen-cab-adc-targeting-nectin4/)
- [Updated Phase 1 and preliminary Phase 2 results from a study of evalstotug (BA3071), an anti–CTLA-4 conditionally active biologic, with or without nivolumab, in advanced solid tumors](https://www.bioatla.com/news/publication/updated-phase-1-and-preliminary-phase-2-results-from-a-study-of-evalstotug-ba3071-an-anti-ctla-4-conditionally-active-biologic-with-or-without-nivolumab-in-advanced-solid-tumors/)
- [A Novel Conditional Active Biologic Anti-EpCAM x Anti-CD3 Bispecific Antibody with Synergistic Tumor Selectivity for Cancer Immunotherapy](https://www.bioatla.com/news/publication/a-novel-conditional-active-biologic-anti-epcam-x-anti-cd3-bispecific-antibody-with-synergistic-tumor-selectivity-for-cancer-immunotherapy/)
- [Evalstotug (BA3071): A potent conditionally active biologic (CAB) anti–CTLA-4 antibody designed to enable high exposures, extended dosing, and reduced immune-mediated toxicity.](https://www.bioatla.com/news/publication/society-of-melanoma-research-21st-international-congress/)
- [Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck](https://www.bioatla.com/news/publication/phase-2-trial-of-ozuriftamab-vedotin-ba3021-a-conditionally-active-biologic-cab-ror2-adc-in-patients-with-recurrent-or-metastatic-squamous-cell-carcinoma-of-the-head-and-neck/)
- [Phase 1 Study of Evalstotug (BA3071), an anti–CTLA-4 Conditionally Active Biologic, in Combination with Nivolumab in Advanced Solid Tumors](https://www.bioatla.com/news/publication/phase-1-study-of-evalstotug-ba3071-an-anti-ctla-4-conditionally-active-biologic-in-combination-with-nivolumab-in-advanced-solid-tumors/)
- [Novel Conditionally Active Biologic Tetravalent T-Cell Engagers Targeting Solid Tumors](https://www.bioatla.com/news/publication/novel-conditionally-active-biologic-tetravalent-t-cell-engagers-targeting-solid-tumors/)
- [Results from a Phase 2 Part 1 Trial of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, in Patients with Advanced Refractory Sarcoma](https://www.bioatla.com/news/publication/results-from-a-phase-2-part-1-trial-of-mecbotamab-vedotin-ba3011-a-cab-axl-adc-in-patients-with-advanced-refractory-sarcoma/)
- [Novel Conditionally Active Tetravalent B7-H3 x CD3 T-cell Engagers Targeting Solid Tumors](https://www.bioatla.com/news/publication/novel-conditionally-active-tetravalent-b7-h3-x-cd3-t-cell-engagers-targeting-solid-tumors/)
- [Conditionally Active Biologics Targeting Novel Senescence Markers Effectively Eliminate the Senescence-Associated Secretory Phenotype in both In Vitro and in Vivo Models](https://www.bioatla.com/news/publication/conditionally-active-biologics-targeting-novel-senescence-markers-effectively-eliminate-the-senescence-associated-secretory-phenotype-in-both-in-vitro-and-in-vivo-models/)
- [Development of A Humanized Anti-IL-22 Antibody for Cancer and Inflammation Therapy](https://www.bioatla.com/news/publication/development-of-a-humanized-anti-il-22-antibody-for-cancer-and-inflammation-therapy/)
- [Conditionally Active Biologic (CAB) ADCs with Novel NextGen Linker Show Improved Efficacy and Safety](https://www.bioatla.com/news/publication/conditionally-active-biologic-cab-adcs-with-novel-nextgen-linker-show-improved-efficacy-and-safety/)
- [First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma: A Case Report](https://www.bioatla.com/news/publication/first-use-of-axl-targeting-in-metastatic-refractory-adenoid-cystic-carcinoma-a-case-report/)
- [A Novel Dual CAB Nectin-4 x CD3 Bispecific Antibody Targeting Solid Tumors](https://www.bioatla.com/news/publication/a-novel-dual-cab-nectin-4-x-cd3-bispecific-antibody-targeting-solid-tumors-3/)
- [A Novel Conditionally Active Bispecific HER2 X CD-3 T Cell Engager Targeting Solid Tumors](https://www.bioatla.com/news/publication/a-novel-conditionally-active-bispecific-her2-x-cd-3-t-cell-engager-targeting-solid-tumors/)
- [Phase 2 Trial of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination With Nivolumab in Patients With Non-Squamous NSCLC](https://www.bioatla.com/news/publication/phase-2-trial-of-mecbotamab-vedotin-ba3011-a-cab-axl-adc-alone-or-in-combination-with-nivolumab-in-patients-with-non-squamous-nsclc/)
- [Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches](https://www.bioatla.com/news/publication/generating-tumor-selective-conditionally-active-biologic-anti-ctla4-antibodies-via-protein-associated-chemical-switches/)
- [A Novel Dual-Cab Nectin-4 X CD3 Bispecific Antibody Targeting Solid Tumors](https://www.bioatla.com/news/publication/a-novel-dual-cab-nectin-4-x-cd3-bispecific-antibody-targeting-solid-tumors-2/)
- [Population Pharmacokinetic and Exposure-Response Safety Analyses of Mecbotamab Vedotin (BA3011) in Patients with Advanced Solid Tumors](https://www.bioatla.com/news/publication/population-pharmacokinetic-and-exposure-response-safety-analyses-of-mecbotamab-vedotin-ba3011-in-patients-with-advanced-solid-tumors/) - Guoxiang George Shen,1 Emily Briggs,2 Ryan Crass,2 Sravan Karumanchi,2 William J Boyle,1 Michael G Baker,1 Philippe Martin11 BioAtla, Inc., San Diego, CA.2 Amador Bioscience, Ann Arbor, MI.BackgroundMecbotamab vedotin (BA3011) is antibody-drug conjugate (ADC) consisting of a conditionally active biologic (CAB) anti-AXL humanized (IgG1) monoclonal antibody conjugated to monomethyl auristatin E (MMAE) using a cleavable linker.
- [Interim Safety and Efficacy Results from Phase 1/2 Study of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, in Patients with Advanced Sarcoma](https://www.bioatla.com/news/publication/interim-safety-and-efficacy-results-from-phase-1-2-study-of-mecbotamab-vedotin-ba3011-a-cab-axl-adc-in-patients-with-advanced-sarcoma/)
- [Conditionally Active Biologics Eliminate Senescence Cells in Cancer and Aging](https://www.bioatla.com/news/publication/conditionally-active-biologics-eliminate-senescence-cells-in-cancer-and-aging/)
- [NextGen Conditionally Active Biologic (CAB) ADCs: Improved Stability and Safety](https://www.bioatla.com/news/publication/nextgen-conditionally-active-biologic-cab-adcs-improved-stability-and-safety-2/)
- [Novel Conditionally Active Bispecific HER2 X CD3 T-Cell Engager Targeting Solid Tumors](https://www.bioatla.com/news/publication/novel-conditionally-active-bispecific-her2-x-cd3-t-cell-engager-targeting-solid-tumors/)
- [NextGen Conditionally Active Biologic (CAB) ADCs: Improved Stability and Safety](https://www.bioatla.com/news/publication/nextgen-conditionally-active-biologic-cab-adcs-improved-stability-and-safety/)
- [A Phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL antibody drug conjugate](https://www.bioatla.com/news/publication/a-phase-1-2-dose-escalation-and-expansion-study-of-a-conditionally-active-anti-axl-antibody-drug-conjugate/)
- [Protein-associated Chemical Switches Differentially Modulate the Binding Activities of Human Apolipoprotein E Isoforms with Their Receptors and with Amyloid Beta Peptides.](https://www.bioatla.com/news/publication/protein-associated-chemical-switches-differentially-modulate-the-binding-activities-of-human-apolipoprotein-e-isoforms-with-their-receptors-and-with-amyloid-beta-peptides/)
- [Novel Conditionally Active Bispecific T Cell Engagers Targeting Solid Tumors](https://www.bioatla.com/news/publication/novel-conditionally-active-bispecific-t-cell-engagers-targeting-solid-tumors-2/)
- [Novel Conditionally Active Bispecific EpCAM x CD3 T Cell Engagers Targeting Solid Tumors](https://www.bioatla.com/news/publication/novel-conditionally-active-bispecific-epcam-x-cd3-t-cell-engagers-targeting-solid-tumors/)
- [Novel conditionally active ADCs (CAB ADCs): A novel class of molecules targeting solid tumors](https://www.bioatla.com/news/publication/novel-conditionally-active-adcs-cab-adcs-a-novel-class-of-molecules-targeting-solid-tumors/)
- [Novel Conditionally Active Bispecific T Cell Engagers Targeting Solid Tumors](https://www.bioatla.com/news/publication/novel-conditionally-active-bispecific-t-cell-engagers-targeting-solid-tumors/)
- [Novel conditionally active biologic (CAB) antibodies](https://www.bioatla.com/news/publication/novel-conditionally-active-biologic-cab-antibodies/)
- [Anti-Tumor Efficacy of BA3021](https://www.bioatla.com/news/publication/anti-tumor-efficacy-of-ba3021/)
- [Potent CAB PD-1 Abs to Reduce Systemic Toxicities Associated with Single Agent and Combination Therapies](https://www.bioatla.com/news/publication/potent-cab-pd-1-abs-to-reduce-systemic-toxicities-associated-with-single-agent-and-combination-therapies/)
- [Anti-Tumor Efficacy of BA3011](https://www.bioatla.com/news/publication/anti-tumor-efficacy-of-ba3011/)
- [Novel Conditionally Active Biologic anti-Axl ADC Demonstrates Anti-Tumor Efficacy and Improved Safety Profile](https://www.bioatla.com/news/publication/novel-conditionally-active-biologic-anti-axl-adc-demonstrates-anti-tumor-efficacy-and-improved-safety-profile/)
## Categories
- [Uncategorized](https://www.bioatla.com/news/category/uncategorized/)
## Platforms
- [CAB-ADCs](https://www.bioatla.com/news/platform/cab-adcs/)
- [CAB Bispecific Antibodies](https://www.bioatla.com/news/platform/cab-bispecific-antibodies/)
- [CAB Technology](https://www.bioatla.com/news/platform/cab-technology/)
- [CAB-Naked Antibodies](https://www.bioatla.com/news/platform/cab-naked-antibodies/)
## Programs
- [AXL](https://www.bioatla.com/news/program/axl/)
- [ROR2](https://www.bioatla.com/news/program/ror2/)
- [EpCam](https://www.bioatla.com/news/program/epcam/)
- [B7-H3](https://www.bioatla.com/news/program/b7-h3/)
- [CD-46](https://www.bioatla.com/news/program/cd-46/)
- [HER-2](https://www.bioatla.com/news/program/her2/)
- [Nectin-4](https://www.bioatla.com/news/program/nectin-4/)
- [CTLA-4](https://www.bioatla.com/news/program/ctla-4/)
- [IL-22](https://www.bioatla.com/news/program/il-22/)
## Years
- [2016](https://www.bioatla.com/news/docyear/2016/)
- [2018](https://www.bioatla.com/news/docyear/2018/)
- [2019](https://www.bioatla.com/news/docyear/2019/)
- [2020](https://www.bioatla.com/news/docyear/2020/)
- [2021](https://www.bioatla.com/news/docyear/2021/)
- [2022](https://www.bioatla.com/news/docyear/2022/)
- [2023](https://www.bioatla.com/news/docyear/2023/)
- [2024](https://www.bioatla.com/news/docyear/2024/)
- [2025](https://www.bioatla.com/news/docyear/2025/)